Skip to main content
2025 IDWeek Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
Live Streamed
On Demand
On Demand

Roy F. Chemaly, MD/MPH (he/him/his)

Gerald P Bodey, Sr Distinguished Professor of Infectious Diseases
University of Texas MD Anderson Cancer Center
Houston, TX, United States

Dr Roy Chemaly is the G. P. Bodey, Sr Distinguished Professor in Infectious Diseases and the newly appointed Chairman of the Department of Infectious Diseases, Infection Control, & Employee Health at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chemaly completed his training in infectious diseases and medical microbiology at the Cleveland Clinic Foundation in Cleveland, Ohio. During his fellowship, Dr. Chemaly completed a master’s degree in public health from Northeastern Ohio Universities in Rootstown, Ohio. Other leadership appointments include the positions of vice-chair and past chair of the Infection Control Committee, the past chair of the Quality and Safety Council of the Division of Internal Medicine, and the past Chief Infection Control Officer at the University of Texas MD Anderson Cancer Center, Houston, Texas.

Dr Chemaly devoted his career studying viral infections in immunocompromised patients, specifically those undergoing hematopoietic cell transplantation (HCT) for hematologic malignancies. He published extensively on mechanisms to treat and prevent viral infections in this population. He contributed in writing and updating the practice guidelines for respiratory viruses, including SARS-CoV-2, in leukemia and HCT and Cellular Therapy patients for three major professional societies; the American Society of Transplantation and Cellular Therapy (ASTCT), the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), and the European Congress for Infectious Complications in Leukemia-8 (ECIL-8). Dr. Chemaly’s work has been reported in numerous high-impact peer-reviewed journals including the New England Journal of Medicine, Blood, Journal of Infectious Diseases, Clinical Microbiology and Infection, and Clinical Infectious Diseases.

Furthermore, Dr Chemaly is very well known on the national and international stages as an expert in clinical and translational virology in immunocompromised hosts. He is the co-chair of the Infection & Immune Reconstitution Working Committee of the ASTCT/CIBMTR, a member of the steering committee for the Transplant Associated Viral Infections (TAVI) that includes representation from the FDA, EMA, experts from national and international academic centers, and industry, the elected Vice-President of the International Immunocompromised Host Society (ICHS), and the chair for the working group on respiratory viruses (ESGREV) of the ESCMID. In addition, he is one of the founding members and past chair of the Transplant Infectious Diseases Special Interest Group of the ASTCT. He received numerous awards in 2022-2023 including the President's Recognition of Faculty Excellence in Prevention Outreach, the Samuel J. Hassenbusch, M.D., Ph.D. Leadership and Institutional Service Award, the Gerald P. Bodey, Sr., Distinguished Professorship Award, all from the University of Texas MD Anderson Cancer Center, and finally the UT Healthcare COVID-19 Hero from the UT System Chancellor's Council Executive Committee, Austin, Texas.

Disclosure(s): ADMA Biologics, Inc.: Advisor/Consultant; AiCuris Anti-Infective Cures AG: Advisor/Consultant, Grant/Research Support; Ansun Biopharma Inc.: Advisor/Consultant, Grant/Research Support; Assembly Bioscience: Advisor/Consultant; Astellas Pharma Inc.: Advisor/Consultant; Eurofins-Viracor: Advisor/Consultant, Grant/Research Support, Honoraria; Gilead Biosciences: Advisor/Consultant; Invivyd, Inc.: Advisor/Consultant; Karius Inc.: Advisor/Consultant, Grant/Research Support; Merck and Company, Inc.: Advisor/Consultant, Grant/Research Support, Honoraria; Moderna, Inc.: Advisor/Consultant; Pfizer Pharmaceutc: Advisor/Consultant; Roche/Genentech: Grant/Research Support; SHIONOGI and CO., LTD.: Advisor/Consultant; Takeda Pharmaceutical: Advisor/Consultant, Grant/Research Support; Tether: Advisor/Consultant

Presentation(s):